Morgan Stanley’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,031
| Closed | -$608 | – | 8270 |
|
|
2024
Q4 | $608 | Hold |
1,031
| – | – | ﹤0.01% | 7326 |
|
|
2024
Q3 | $813 | Hold |
1,031
| – | – | ﹤0.01% | 7254 |
|
|
2024
Q2 | $1.31K | Sell |
1,031
-6
| -0.6% | -$8 | ﹤0.01% | 7125 |
|
|
2024
Q1 | $1.44K | Buy |
1,037
+624
| +151% | +$1.03K | ﹤0.01% | 7125 |
|
|
2023
Q4 | $657 | Hold |
413
| – | – | ﹤0.01% | 7177 |
|
|
2023
Q3 | $586 | Hold |
413
| – | – | ﹤0.01% | 7292 |
|
|
2023
Q2 | $657 | Sell |
413
-30
| -7% | -$38 | ﹤0.01% | 7350 |
|
|
2023
Q1 | $372 | Hold |
443
| – | – | ﹤0.01% | 7462 |
|
|
2022
Q4 | $629 | Hold |
443
| – | – | ﹤0.01% | 7533 |
|
|
2022
Q3 | $1K | Hold |
443
| – | – | ﹤0.01% | 7621 |
|
|
2022
Q2 | $1K | Sell |
443
-60
| -12% | -$145 | ﹤0.01% | 7717 |
|
|
2022
Q1 | $2K | Sell |
503
-300
| -37% | -$1.05K | ﹤0.01% | 7769 |
|
|
2021
Q4 | $3K | Buy |
803
+300
| +60% | +$1.7K | ﹤0.01% | 7754 |
|
|
2021
Q3 | $3K | Sell |
503
-900
| -64% | -$7.04K | ﹤0.01% | 7615 |
|
|
2021
Q2 | $14K | Buy |
1,403
+900
| +179% | +$7.54K | ﹤0.01% | 7139 |
|
|
2021
Q1 | $4K | Buy |
503
+413
| +459% | +$3.44K | ﹤0.01% | 7170 |
|
|
2020
Q4 | $0 | Buy |
+90
| New | +$422 | ﹤0.01% | 7136 |
|
Morgan Stanley's CYTH Position: Q1 2025 in Review
Morgan Stanley sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 1,031 shares — an estimated $608 sold.
Morgan Stanley first reported a position in CYTH in Q4 2020 and held it in 17 quarters. The position peaked at $14K in Q2 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- Morgan Stanley reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Morgan Stanley sold 1,031 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $608.
- Morgan Stanley first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
- Morgan Stanley's Cyclo Therapeutics, Inc. Common Stock position peaked at $14K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.